Premium
Targeting of EGF‐displayed protein nanoparticles with anticancer drugs
Author(s) -
Matsumoto Rie,
Hara Rieko,
Andou Takashi,
Mie Masayasu,
Kobatake Eiry
Publication year - 2014
Publication title -
journal of biomedical materials research part b: applied biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.665
H-Index - 108
eISSN - 1552-4981
pISSN - 1552-4973
DOI - 10.1002/jbm.b.33162
Subject(s) - nanoparticle , epidermal growth factor , paclitaxel , elastin , drug delivery , aspartic acid , chemistry , targeted drug delivery , drug carrier , biophysics , receptor , amino acid , materials science , nanotechnology , biochemistry , biology , cancer , genetics
The development of protein‐based carriers for drug delivery has been well studied. We previously constructed a protein‐based nanoparticle consisting of genetically engineered elastin‐like polypeptides (ELPs) with a fused poly‐aspartic acid tail (ELP D ). The size of the self‐assembled ELP D nanoparticles was regulated by charged repulsion of the poly‐aspartic acid chains. In the present study, epidermal growth factor (EGF) was genetically fused to the C‐terminus of ELP D to impart an active targeting ability to the ELP D nanoparticles. We examined the nanoparticle formation with EGF as well as its targeting ability. ELP D with fused EGF was found to form nanoparticles that displayed multivalent EGFs on their surface. EGF‐displayed nanoparticles loaded with the anti‐cancer drug paclitaxel were internalized into cells overexpressing the EGF receptor, and induced cell death. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 102B: 1792–1798, 2014.